P0628 Patient preferences towards treatment attributes in Inflammatory Bowel Disease: a Brazilian cohort study

Abstract

Listen

Translate article

Abstract Background Inflammatory bowel disease (IBD) is a chronic condition of the gastrointestinal tract characterised by recurring inflammation that usually requires life-long treatment. As the therapeutic landscape is rapidly expanding, there is a growing need to understand patient perceptions of treatment-related attributes. This study explored the preferences for treatment attributes in patients with Crohn’s disease (CD) or ulcerative colitis (UC) in Brazil. Methods Adult patients from Argentina, Australia, Brazil, Saudi Arabia and Taiwan who self-reported diagnosis of CD or UC participated in an online survey. In a discrete choice experiment, the relative importance of treatment attributes for CD or UC was estimated using conditional and multinomial logit models. Results In Brazil, 200 patients completed survey responses (CD, n = 100; UC, n = 100), with mean patient ages of 34.9±7.9 and 36.1±9.4 years, respectively. Most patients were covered by private insurance, and the majority had been exposed to advanced therapies (74% for CD and 62% for UC). These patients were primarily treated at IBD centers and private hospitals, with a higher percentage reporting general good or fair well-being (82% for CD and 85% for UC). Patients with CD ranked long-term remission on maintenance therapy (34.8%), the rate of 1-year remission (26.2%), and the route of administration (22.3%) as the most important attributes. Patients with UC prioritized corticosteroid-free remission after 1 year (30.3%), the route of administration (30.1%), and the rate of mucosal healing after 1 year (16.2%). Both CD and UC patients considered abdominal pain as the most impactful symptom on their daily lives. General and emotional well-being were rated as the first and second most important aspects for improvement through treatment. Conclusion Patient preferences for treatment attributes correlate with CD or UC clinical manifestations and management, highlighting the importance of personalised care and shared decision-making to maximize treatment benefits and provide valuable insights for the stakeholders involved from drug development to treatment access.